Beverly L Davidson
Overview
Explore the profile of Beverly L Davidson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
188
Citations
9649
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
ODriscoll E, Arora S, Lang J, Davidson B, Shalem O
Mol Ther Methods Clin Dev
. 2025 Feb;
33(1):101408.
PMID: 39980803
Recombinant adeno-associated virus (rAAV) vectors are an effective and well-established tool in the growing gene therapy field, with five U.S. Food and Drug Administration-approved AAV-mediated gene therapies already on the...
2.
Devinsky O, Coller J, Ahrens-Nicklas R, Liu X, Ahituv N, Davidson B, et al.
Trends Mol Med
. 2025 Feb;
PMID: 39966070
Pathogenic variants in over 1700 genes can cause neurogenetic disorders. Monogenetic diseases are ideal targets for genetic therapies; however, the blood-brain barrier (BBB), post-mitotic neurons, and inefficient delivery platforms make...
3.
Nguyen L, Ajredini R, Guo S, Romano L, Tomas R, Bell L, et al.
Proc Natl Acad Sci U S A
. 2025 Feb;
122(7):e2416885122.
PMID: 39937857
Alzheimer's disease (AD) affects more than 10% of the population ≥65 y of age, but the underlying biological risks of most AD cases are unclear. We show anti-poly-glycine-arginine (a-polyGR) positive...
4.
ODriscoll E, Arora S, Lang J, Davidson B, Shalem O
bioRxiv
. 2024 Sep;
PMID: 39345423
Recombinant adeno-associated virus (rAAV) vectors are an effective and well-established tool in the growing gene therapy field, with five FDA-approved AAV-mediated gene therapies already on the market and numerous more...
5.
Fagan K, Chillon G, Carrell E, Waxman E, Davidson B
Mol Ther Nucleic Acids
. 2024 Sep;
35(4):102317.
PMID: 39314800
Spinocerebellar ataxia type 1 (SCA1) is an adult-onset neurodegenerative disease caused by an expansion of the CAG repeat region of the gene. Currently there are no disease-modifying treatments; however, previous...
6.
Felix A, Wilson T, Randell R, Marotta N, Uchida K, Boland M, et al.
bioRxiv
. 2024 Sep;
PMID: 39229131
Heterozygous variants in and lead to distinct neurodevelopmental disorders caused by haploinsufficient levels of post-synaptic SYNGAP1 and pre-synaptic STXBP1, which are critical for normal synaptic function. While several gene-targeted therapeutic...
7.
Liu X, Jean-Gilles R, Baginski J, Cai C, Yan R, Zhang L, et al.
Mol Ther Methods Clin Dev
. 2024 Aug;
32(3):101298.
PMID: 39170800
Recombinant adeno-associated virus (rAAV)-based gene therapies are expanding in their application. Despite progress in manufacturing, current analytical methods for product quantification and characterization remain largely unchanged. Although critical for product...
8.
Weber J, Lang J, Carrell E, Alameh M, Davidson B
Mol Ther Nucleic Acids
. 2024 Jul;
35(2):102172.
PMID: 38978694
Clinical application of CRISPR-Cas9 technology for large deletions of somatic mutations is inefficient, and methods to improve utility suffer from our inability to rapidly assess mono- vs. biallelic deletions. Here...
9.
Jackson R, Keiser M, Meltzer J, Fykstra D, Dierksmeier S, Hajizadeh S, et al.
Mol Ther
. 2024 Mar;
32(5):1373-1386.
PMID: 38504517
Epidemiological studies show that individuals who carry the relatively uncommon APOE ε2 allele rarely develop Alzheimer disease, and if they do, they have a later age of onset, milder clinical...
10.
Amado D, Robbins A, Smith A, Whiteman K, Chillon Bosch G, Chen Y, et al.
bioRxiv
. 2024 Feb;
PMID: 38352376
Amyotrophic lateral sclerosis (ALS) is characterized by motor neuron death due to nuclear loss and cytoplasmic aggregation of the splice factor TDP-43. Pathologic TDP-43 associates with stress granules (SGs) and...